skip to main content

SciTech ConnectSciTech Connect

Title: Adipose-derived stem cells retain their regenerative potential after methotrexate treatment

In musculoskeletal tissues like bone, chemotherapy can impair progenitor cell differentiation and proliferation, resulting in decreased bone growth and mineralization throughout a patient's lifetime. In the current study, we investigated the effects of chemotherapeutics on adipose-derived stem cell (ASC) function to determine whether this cell source could be a candidate for repairing, or even preventing, chemotherapy-induced tissue damage. Dose-dependent proliferation rates of ASCs and normal human fibroblasts (NHFs) were quantified after treatment with cytarabine (CY), etoposide (ETO), methotrexate (MTX), and vincristine (VIN) using a fluorescence-based assay. The influence of MTX on the multipotency of ASCs and freshly isolated stromal vascular fraction (SVF) cells was also evaluated using lineage-specific stains and spectrophotometry. ASC and NHF proliferation were equally inhibited by exposure to CY and ETO; however, when treated with MTX and VIN, ASCs exhibited greater resistance. This was especially apparent for MTX-treated samples, with ASC proliferation showing no inhibition for clinically relevant MTX doses ranging from 0.1 to 50 μM. Additional experiments revealed that the differentiation potential of ASCs was not affected by MTX treatment and that upregulation of dihydrofolate reductase possibly contributed to this response. Moreover, SVF cells, which include ASCs, exhibited similar resistance to MTX impairment, with respect tomore » cellular proliferation, clonogenicity, and differentiation capability. Therefore, we have shown that the regenerative properties of ASCs resist the cytotoxicity of MTX, identifying these cells as a potential key for repairing musculoskeletal damage in patients undergoing chemotherapy. - Highlights: • Long-term effects of chemotherapeutics can include musculoskeletal dysfunction. • A screen of common drugs showed disparate effects on ASCs and fibroblasts. • One drug, methotrexate, did not impair ASC growth characteristics or multipotency. • Upregulation of dihydrofolate reductase may enable ASC methotrexate resistance. • ASCs thus pose a possible means to ameliorate long-term tissue damage.« less
Authors:
 [1] ;  [2] ;  [1] ;  [3] ;  [3] ;  [3]
  1. Center for Biomedical Engineering, Brown University, Providence, RI (United States)
  2. Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, RI (United States)
  3. (United States)
Publication Date:
OSTI Identifier:
22416933
Resource Type:
Journal Article
Resource Relation:
Journal Name: Experimental Cell Research; Journal Volume: 327; Journal Issue: 2; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTHERAPY; COLONY FORMING UNITS; FIBROBLASTS; FLUORESCENCE; METHOTREXATE; PLANT GROWTH; SKELETON; SPECTROPHOTOMETRY; STEM CELLS; TOXICITY